Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.

World Journal of Gastroenterology : WJG
Jian LiLin Shen

Abstract

To investigate the efficacy and safety of imatinib dose escalation in Chinese patients with advanced gastrointestinal stromal tumor (GIST). Advanced GIST patients previously failing 400 mg imatinib treatment were enrolled in this study. Patients received imatinib with dose escalation to 600 mg/d, and further dose escalation to 800 mg/d if imatinib 600 mg/d failed. Progression-free survival, overall survival, clinical efficacy, c-kit/PDGFRA genotype and safety were evaluated. 52 patients were enrolled in this study. For the 47 evaluable patients receiving imatinib (600 mg/d), the disease control rate was 40.4%, and the median progression-free survival for all patients was 17 wk (95% CI: 3.9-30.1). The median overall survival after dose escalation was 81 wk (95% CI: 36.2-125.8). Adverse events, mainly edema, fatigue, granulocytopenia and skin rash were tolerable. However, further dose escalation (800 mg/d) in 14 cases was ineffective, with disease progression and severe adverse events. Among 30 cases examined for gene mutations, patients with exon 9 mutations experienced a better progression-free survival of 47 wk. Imatinib dose escalation to 600 mg/d is more appropriate for Chinese patients and may achieve further survival benefit.

References

Nov 14, 2001·Lancet·A T van OosteromUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Nov 9, 2002·The Lancet Oncology·Heikki JoensuuGeorge Demetri
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
Jul 24, 2004·Expert Review of Anticancer Therapy·Alicia TosoniAlba A Brandes
Aug 16, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·John R ZalcbergUNKNOWN Australasian Gastrointestinal Trials Group
Jul 18, 2006·British Journal of Clinical Pharmacology·N WidmerT Buclin
Jan 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Narasimhan P AgaramCristina R Antonescu
Feb 1, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Shreyaskumar Patel, John R Zalcberg

❮ Previous
Next ❯

Citations

Aug 8, 2013·Journal of Gastrointestinal Cancer·T Reid
Jan 18, 2013·World Journal of Gastroenterology : WJG·Mehmet Ali Nahit SendurSercan Aksoy
Sep 15, 2016·Clinical Genitourinary Cancer·Moshe C OrnsteinBrian I Rini
Jun 9, 2019·European Journal of Clinical Pharmacology·Stefanie L GroenlandNeeltje Steeghs
Dec 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ipek Özer-StillmanKatherine E Tranbarger-Freier

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.